Constellium SE benefits from secular demand in aerospace and automotive lightweighting, and a robust capital allocation plan.
JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results